TWiV 686: COVID-19 clinical update #38 with Dr. Daniel Griffin
About this episode
Daniel Griffin provides his weekly clinical report on COVID-19, including new post-exposure guidelines from CDC, clinical trials of Remdesivir and convalescent plasma, FDA EUA for baricitinib and Regeneron's monoclonal antibody and more.
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- WHO Solidarity trial for Remdesivir and other drugs (medRxiv)
- EUA for Baricitinib (FDA)
- EUA for Casirivimab and Imdevimab (FDA)
- RCT: No benefit of convalescent plasma (NEJM)
- Letters read on TWiV 686
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your virology questions and comments to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology